{"product_id":"vrtx-marketing-mix","title":"Vertex Pharmaceuticals Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVertex Pharmaceuticals leverages a specialized product portfolio focused on transformative therapies, premium pricing reflecting R\u0026amp;D value, targeted distribution through specialist channels, and science-led promotion to clinicians and patient communities—discover how these elements combine to sustain its market leadership. Get the full 4Ps Marketing Mix Analysis in an editable, presentation-ready format to save hours of research and apply actionable insights to your strategy or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Cystic Fibrosis Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVertex holds a near-monopoly in cystic fibrosis via CFTR modulators, led by Trikafta\/Kaftrio and, by end-2025, largely transitioned patients to vanzacaftor\/tezacaftor\/deutivacaftor; these modulators target the disease mechanism and cover ~90% of people with CF.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Gene Editing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe commercialization of Casgevy, the one-time CRISPR\/Cas9 infusion for sickle cell disease and transfusion-dependent beta thalassemia developed with CRISPR Therapeutics, shifts Vertex toward curative, high-value personalized medicine.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Casgevy accounted for roughly $650 million in non-CF revenue, anchoring a new product cohort and reducing CF dependence to about 55% of total sales.\u003c\/p\u003e\n\u003cp\u003eTargeting the root genetic defect, the therapy supports premium pricing and lower recurring revenue risk but adds launch costs: estimated $120–180k per treated patient and a $200–300m channel and manufacturing buildout through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcute and Peripheral Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertex expanded its portfolio with suzetrigine, a selective NaV1.8 blocker for moderate-to-severe acute pain, launched 2025 and positioned as a non-addictive alternative to opioids; US acute pain market ≈ $4.5B in 2024, offering clear revenue upside.\u003c\/p\u003e\n\u003cp\u003ePipeline includes Phase 3 diabetic peripheral neuropathy trials (started 2024), aiming at a neuropathic pain market of ~$6.2B by 2028, pushing Vertex into primary care and specialty pain clinics and diversifying revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKidney and Rare Disease Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy 2025 Vertex’s product mix includes advanced-stage APOL1-targeted therapies and an investigational treatment for Alpha-1 antitrypsin deficiency, expanding beyond cystic fibrosis.\u003c\/p\u003e\n\u003cp\u003eThese programs use Vertex’s protein-folding and genetic-drivers expertise to address high unmet needs in kidney and rare lung disease, with combined market opportunity estimates \u0026gt;$8B by 2030.\u003c\/p\u003e\n\u003cp\u003eThis diversification cuts CF revenue concentration (CF sales were $8.6B in 2024) and positions Vertex as a multi-disease biotech leader.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAPOL1 and AATD: late-stage in 2025\u003c\/li\u003e\n\u003cli\u003eTarget market \u0026gt;$8B by 2030\u003c\/li\u003e\n\u003cli\u003eCF sales 2024: $8.6B\u003c\/li\u003e\n\u003cli\u003eReduces CF dependence, boosts pipeline breadth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eType 1 Diabetes Cell Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVertex Pharmaceuticals is developing potentially curative cell therapies for Type 1 Diabetes, notably VX-880 and VX-264, designed to replace insulin-producing islet cells using stem cell-derived approaches to restore glucose control.\u003c\/p\u003e\n\u003cp\u003eAs of 2025 VX-880 showed early efficacy with insulin independence signals in Phase 1\/2 cohorts and Vertex reported R\u0026amp;D spend of $3.2B in 2024, underscoring long-term investment in regenerative medicine.\u003c\/p\u003e\n\u003cp\u003eThese candidates remain clinical-stage but anchor Vertex’s product strategy to pursue functional cures for chronic autoimmune diseases, targeting large addressable markets—~1.5M US T1D patients and global market \u0026gt;$20B.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVX-880, VX-264: stem cell-derived islet replacement\u003c\/li\u003e\n\u003cli\u003ePhase: clinical (Phase 1\/2 as of 2025)\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D spend: $3.2B\u003c\/li\u003e\n\u003cli\u003eAddressable market: ~1.5M US patients; global \u0026gt;$20B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertex pivots from CF reliance to diversified blockbuster pipeline and gene cures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertex shifted from CF concentration (2024 CF sales $8.6B, ~55% of 2025 revenue) toward diversified high-value products: Trikafta\/Kaftrio and next-gen modulators (~90% CF coverage), Casgevy (CRISPR one-time; ~$650M 2025 non-CF revenue), suzetrigine (2025 acute pain launch; US market $4.5B), APOL1\/AATD late-stage, VX-880\/VX-264 T1D programs; 2024 R\u0026amp;D $3.2B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25 Status\u003c\/th\u003e\n\u003cth\u003eKey 2025 numbers\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCFTR modulators\u003c\/td\u003e\n\u003ctd\u003eMarket leader\u003c\/td\u003e\n\u003ctd\u003eCF sales $8.6B (2024); ~90% CF coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCasgevy\u003c\/td\u003e\n\u003ctd\u003eLaunched\u003c\/td\u003e\n\u003ctd\u003e$650M non-CF revenue (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuzetrigine\u003c\/td\u003e\n\u003ctd\u003eLaunched 2025\u003c\/td\u003e\n\u003ctd\u003eUS acute pain market $4.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVX-880\/264\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2\u003c\/td\u003e\n\u003ctd\u003e~1.5M US T1D pts; global \u0026gt;$20B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPOL1\/AATD\u003c\/td\u003e\n\u003ctd\u003eLate-stage\u003c\/td\u003e\n\u003ctd\u003eCombined market \u0026gt;$8B by 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Vertex Pharmaceuticals’ Product, Price, Place, and Promotion strategies, ideal for managers, consultants, and marketers seeking a clear breakdown of its marketing positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Vertex Pharmaceuticals’ 4P marketing mix into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotional focus, and distribution channels to accelerate strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Specialized Treatment Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVertex restricts Casgevy distribution to Authorized Treatment Centers (ATCs) that can handle cell and gene therapies; as of 2025 there are ~45 ATCs across the US, Europe, and Middle East, concentrated in major medical hubs to manage complex care and AEs.\u003c\/p\u003e\n\u003cp\u003eThese ATCs are co-located with manufacturing touchpoints—vein-to-vein supply chains—so patient cell harvest, re-engineering, and infusion are integrated; this reduces transit times to under 72 hours in 80% of cases and supports quality-control and reimbursement workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Pharmacy Specialty Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVertex directs oral drugs like Trikafta and suzetrigine through a specialty pharmacy network instead of retail, delivering high-touch services—adherence monitoring and insurance support—to patients; in 2024 Vertex’s net product sales hit $9.3B, with Trikafta-class sales driving the bulk. By selecting partners and controlling distribution, Vertex tightly manages inventory and cold-chain needs for high-value, temperature-sensitive meds, reducing fill times and shrinkage. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Access and Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertex Pharmaceuticals focuses sales in North America, the EU, and Australia, where public payers fund high-cost biotech; these regions accounted for about 82% of 2024 product revenue ($8.9B of $10.9B). Vertex negotiates directly with national health services and private insurers to secure formulary placement and outcomes-based contracts, lowering payer budget impact. By late 2025 Vertex expanded into targeted emerging markets—Brazil, South Africa, and parts of Southeast Asia—addressing cystic fibrosis and blood-disorder prevalence and adding roughly 4–6% incremental market reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVertex Pharmaceuticals invested over $1.4 billion by 2024 in in-house manufacturing, including a Boston cell and gene therapy facility opened in 2021, enabling vertical control from production to delivery and reducing third-party supply risks.\u003c\/p\u003e\n\u003cp\u003eLocalized manufacturing supports time-sensitive procedures—Vertex reports \u0026gt;95% on-time delivery for advanced therapies in 2024—improving patient access and clinical scheduling reliability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;$1.4B capex by 2024\u003c\/li\u003e\n\u003cli\u003eBoston cell\/gene site online 2021\u003c\/li\u003e\n\u003cli\u003e\u0026gt;95% on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003eReduced third-party dependency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Remote Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVertex uses digital platforms to deliver patient and clinician support, hosting prescription management, shipment tracking, and telehealth for therapy starts; in 2024 Vertex reported over 200,000 digital patient interactions tied to CF therapies.\u003c\/p\u003e\n\u003cp\u003eThese portals sit alongside physical drug distribution, improving access for patients distant from major centers and reducing initiation delays—Vertex noted a 15% faster therapy start where digital support was used in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200,000+ digital interactions in 2024\u003c\/li\u003e\n\u003cli\u003ePrescription management, shipment tracking, telehealth\u003c\/li\u003e\n\u003cli\u003e15% faster therapy initiation with digital support (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertex scales advanced therapies: ~45 ATCs, $1.4B+ capex, 95%+ on-time delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertex centralizes advanced-therapy delivery at ~45 Authorized Treatment Centers (2025) and routes small-molecule drugs via specialty pharmacies; in 2024 capex exceeded $1.4B with a Boston cell\/gene site (online 2021), \u0026gt;95% on-time delivery for ATC therapies, 200,000+ digital patient interactions, and 82% of 2024 revenue from NA\/EU\/Australia.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuthorized Treatment Centers (2025)\u003c\/td\u003e\n\u003ctd\u003e~45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex by 2024\u003c\/td\u003e\n\u003ctd\u003e$1.4B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital interactions (2024)\u003c\/td\u003e\n\u003ctd\u003e200,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue share: NA\/EU\/Australia (2024)\u003c\/td\u003e\n\u003ctd\u003e82%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVertex Pharmaceuticals 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Vertex Pharmaceuticals 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete and ready to use, with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750746141049,"sku":"vrtx-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/vrtx-marketing-mix.png?v=1772226118","url":"https:\/\/growthsharematrix.com\/products\/vrtx-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}